Dr. Michael Hantman is the Associate Director of Methods Development for Charles River’s Biologics site in Pennsylvania. He and his team have developed and validated over 250 methods to detect/quantitate adventitious agents in biopharmaceuticals and characterizing substrates used in the production of biopharmaceuticals. Some of the substrates include quantitative qPCR assays for specific and broad-range targets, residual HCD/sizing, and copy number.
Michael received his PhD in microbiology and immunology from Temple University’s School of Medicine. He conducted postdoctoral fellowships at Harvard Medical School, Massachusetts General Hospital, and the University of Washington focusing on vaccine development and host-pathogen interactions using recombinant, attenuated salmonella strains expressing heterologous genes to stimulate immune pathways.